PSD-95/nNOS PPI-IN-1
PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (Ki = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke.
For research use only. We do not sell to patients.
- Formula: C32H41N5O8S
- Molecular Weight:655.76
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All iGluR Isoforms
More
Biological Activity
PSD-95/nNOS PPI-IN-1 (Compound 32-2) (0.1-10 μM, 2 h pretreatment) significantly increases cell viability of HT22 cells injured by glutamate[1].
PSD-95/nNOS PPI-IN-1 (10-20 μM, 2 h pretreatment) significantly enhances cell viability of primary cortical neurons (cultured for 9 days) injured by glutamate[1].
PSD-95/nNOS PPI-IN-1 (10 μM, 2 h pretreatment) significantly reduces glutamate -induced intracellular ROS levels in HT22 cells[1].
PSD-95/nNOS PPI-IN-1 (10 μM, 2 h pretreatment) significantly upregulates Bcl-2 protein expression and downregulates Bax and cleaved-caspase 3 protein expressions in HT22 cells treated with glutamate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT22 cells treated with glutamate
-
Concentration:10 μM
-
Incubation Time:2 h pretreatment
-
Result:Upregulated Bcl-2 protein expression and downregulated Bax and Cleaved-caspase 3 protein expressions.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male SD rats (220-280 g) underwent transient middle cerebral artery occlusion (tMCAO) by inserting a 4/0 nylon monofilament via the external carotid artery to occlude the middle cerebral artery for 1.5 h, followed by reperfusion[1]
-
Dosage:8 mg/kg
-
Administration:i.v., once at 2 h post-reperfusion
-
Result:Achieved a significant reduction in cerebral infarct volume from 32.64% (model group) to 25.28%.
Showed neuroprotective effect in reducing cerebral infarct volume.
Chemical Information
-
Molecular Weight 655.76
-
Formula C32H41N5O8S
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)